|
|
||||||||
CC Peck, WH Barr, LZ Benet, J Collins, RE Desjardins, DE Furst, JG Harter, G Levy, T Ludden, JH Rodman, and al. et
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
Article topics:
This article has been cited by other articles:
![]() |
D. E. Mager, E. Wyska, and W. J. Jusko Diversity of Mechanism-Based Pharmacodynamic Models Drug Metab. Dispos., May 1, 2003; 31(5): 510 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S Cohen Why Aren't Lower, Effective, OTC Doses Available Earlier by Prescription? Ann. Pharmacother., January 1, 2003; 37(1): 136 - 142. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Cohen Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events Arch Intern Med, April 9, 2001; 161(7): 957 - 964. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-C. Shin, H.-O. Shim, S.-C. Ahn, J.-H. Cho, M.-K. Chung, S.-S. Han, and J.-K. Roh Pharmacokinetic Analysis for Assessing Developmental Toxicity of a New Synthetic Acetolactate Synthase Inhibitor, LGC-40863, in Rats J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 795 - 799. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||